Genetic Cancer Susceptibility Group
Identifying the genes involved in cancer development leads to a greater understanding of the biological pathways involved in the carcinogenic process and, through the observation of gene–environment interactions, can elucidate how environmental factors exert their effects. It also has increasing utility in risk management, detection, diagnosis, and the clinical management of many types of cancer. Within its research goals, the Genetic Cancer Susceptibility Group (GCS) aims to describe the genes involved in cancer susceptibility and development and, subsequently, how they exert their effects. GCS uses a multidisciplinary genomic approach, integrating data from genetics, pathology, epidemiology, and multi-genomic techniques to assist the Group′s research.
GCS works on common cancers, such as lung cancer, but tends to focus on rare cancers, such as those of the head and neck (including oesophageal and nasopharyngeal cancers), kidney and thoracic tumours, and lymphomas. In addition, GCS is exploring the potential for genomic techniques to be used as measures of circulating genomic biomarkers, testing their utility as mechanisms of minimally invasive early detection and surveillance of cancer.
The final role of GCS is to support the Agency′s capacity in genomics. GCS aims to adapt laboratory, pathology, and bioinformatics-related genomic techniques to suit IARC′s particular needs and mission, and to support genomics-related activities across the Agency through the Genetics Platform (GSP).